|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multivariate logistic regression showed that PSA (OR: 1.005; 95%CI: 1.001-1.010; P=0.016), Gleason score (OR: 4.095; 95%CI: 1.592-10.529; P=0.003), and AR expression (OR: 14.023; 95%CI: 3.531-55.6981; P=0.005) were independently associated with bone metastases.
|
28400549 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
|
21552559 |
2011 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sub-groups of bone metastases could be identified according to their expression levels of AKR1C3 and AR-Vs, which might be of relevance for patient response to 2(nd) line androgen-deprivation therapy.
|
24244276 |
2013 |
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.
|
8717468 |
1996 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In an established breast cancer xenograft model, a bone-tropic derivative displays increased AR expression, whose genetic or pharmacologic suppression reduces metastases to bone but not to lungs.
|
29453314 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
No association was found between p21 expression and p53, bcl-2, and the androgen receptor protein expression in bone metastases of patients with AIPC, whereas there was a significant association with a high Ki-67 index (P < 0.05).
|
11895908 |
2002 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The latest approvals include abiraterone acetate, enzalutamide and apalutamide which target androgen receptor (AR) signaling, radium-223 dichloride for reduction of bone metastases, sipuleucel-T immunotherapy and taxane-based chemotherapy.
|
29734647 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The majority of CRPC bone metastases (80%) was defined as AR-driven based on PCA analysis and high expression of the AR, AR co-regulators (FOXA1, HOXB13), and AR-regulated genes (KLK2, KLK3, NKX3.1, STEAP2, TMPRSS2); 20% were non-AR-driven.
|
27497761 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have characterized the androgen receptor (AR) in a new human prostate cancer cell line, MDA PCa 2a, that has recently been established from a bone metastasis of a patient whose cancer exhibited androgen-independent growth.
|
10569618 |
1999 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, the current study specifically investigated bone cell activity in clinical bone metastases in relation to tumor cell AR activity, in order to gain novel insight into biological heterogeneities of possible importance for patient stratification into bone-targeting therapies.
|
29670000 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.
|
12237884 |
2002 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specific aim was to examine AR amplification in PC bone metastases and to explore molecular and functional consequences of this, with the long-term goal of identifying novel molecular targets for treatment.
|
28144969 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By comparing expression profiles of primary prostate cancer biopsies, with and without bone metastasis, we discovered that the expression of activin A is increased in cases with bone metastatic propensity and correlates with increased androgen receptor (AR), PSA expression, and Gleason scores.
|
19257827 |
2009 |